Skip to main content

6Node page

what any key link opens

psx:substance/morning-glory/claim/762c812e-03ad-4c31-90bc-74cf94806b2f

claim2026-05-14recordsupported

feeds · downstream

Closure of psx:substance/morning-glory/claim/762c812e-03ad-4c31-90bc-74cf94806b2f: 45 upstream, 57 downstream.

psx:substance/morning-glory/claim/762c812e-03ad-4c31-90bc-74cf94806b2f
├─ used  src/doi:10.3390/toxins7041355  The key role of peltate glandular trichomes in symbiota comprising clavicipitaceous fungi of the genus Periglandula and their host plants
  ├─ informed_by  claim/a4422cc6-81ca-451f-bd5b-3c6fa336607e  Claim in alkaloid-profile — inconclusive  working
  ├─ informed_by  claim/ffaa59e5-6fbc-4894-bd72-baeac9c22f6b  Claim in alkaloid-profile — inconclusive  working
  ├─ informed_by  claim/e2a4258e-fdab-4910-8606-fb0255570256  Claim in alkaloid-profile — supported
  ├─ informed_by  claim/8b682b8a-f045-454d-89a9-57de5eb09f55  Claim in alkaloid-profile — supported
  ├─ informed_by  claim/83b026ec-5aed-4260-9530-004fcf3cb157  Claim in alkaloid-profile — supported
  ├─ informed_by  claim/4c7da947-2296-4d5c-b28a-bb2c7d972ce9  Claim in alkaloid-profile — supported
    ├─ used  src/doi:10.1080/00275514.2025.2483634  A new species of Periglandula symbiotic with the morning glory Ipomoea tricolor
    ├─ used  src/doi:10.1016/j.neuropharm.2011.01.017  Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens
    ├─ used  src/pmid:23662334  Recreational use of D-lysergamide from the seeds of Argyreia nervosa, Ipomoea tricolor, Ipomoea violacea, and Ipomoea purpurea in Poland
    ├─ used  src/doi:10.1007/s00216-016-9322-5  Identification and determination of ergot alkaloids in Morning Glory cultivars
    ├─ used  src/doi:10.1016/j.forsciint.2011.06.025  Variable adverse effects in subjects after ingestion of equal doses of Argyreia nervosa seeds
    ├─ used  src/doi:10.1016/j.forsciint.2009.11.017  Two cases of lysergamide intoxication by ingestion of seeds from Hawaiian Baby Woodrose
    ├─ used  src/doi:10.1080/17512433.2023.2279192  Stimulant and hallucinogenic novel psychoactive substances; an update
    ├─ used  src/doi:10.1590/s0102-695x2012005000025  Ipomoea genus review — traditional uses, chemistry, and biological activities
    ├─ used  src/doi:10.1055/a-0577-8049  Ergot Alkaloids and their Hallucinogenic Potential in Morning Glories
    ├─ used  src/doi:10.1111/nph.18785  Phylogenetic patterns of bioactive secondary metabolites produced by fungal endosymbionts in morning glories (Ipomoeeae, Convolvulaceae)
    ├─ used  src/doi:10.1590/2175-7860202172034  Distribution of Ipomoea violacea (Convolvulaceae): patterns, gaps and reports for its occurrence in Brazil and West Tropical Africa
    ├─ used  src/doi:10.1186/s41935-017-0016-8  GC/MS analysis of morning glory seeds freely in commerce: can they be considered herbal highs?
    ├─ used  src/doi:10.1007/s10886-019-01109-w  Decreased Root-Knot Nematode Gall Formation in Roots of the Morning Glory Ipomoea tricolor Symbiotic with Ergot Alkaloid-Producing Fungal Periglandula Sp.
    ├─ used  src/doi:10.1007/s00253-024-13157-8  An unexpected role of EasD: catalyzing the conversion of chanoclavine aldehyde to chanoclavine acid
    ├─ used  src/doi:10.3390/jof8080823  How and Where Periglandula Fungus Interacts with Different Parts of Ipomoea asarifolia
    ├─ used  src/doi:10.2174/1570159X14666161031144427
    ├─ used  src/doi:10.1208/s12248-008-9028-5  Indolealkylamines: biotransformations and potential drug-drug interactions
    ├─ used  src/pmid:3087616  Ergotamine tartrate dependency: features and possible mechanisms
    ├─ used  src/doi:10.1007/s40263-012-0002-5  Drug interactions with triptans: which are clinically significant?
    ├─ derived_from  gen/dcccb9b8-bd4e-4383-a587-a5dfc46f1d62  Generation — pipeline-v5
    ├─ generated_by  pub/6b752e98-8c0e-40a1-a5db-48c4eadfcfe0  Publication — backfill
      ├─ used  search/7a49fe9f-68ad-485b-a051-1cd07e2007cc  Searched OpenAlex for "morning glory Ipomoea ergine lysergic acid amide psychoactive"
      ├─ used  search/a4f2cd9e-24d9-49dd-9fc2-8ceb3ec6bb78  Searched PubChem for "ergine / lysergic acid amide"
      ├─ used  search/ca7cf66b-afd4-426c-93b6-1e6696df8fcd  Searched PubMed for "Ipomoea violacea ergot alkaloids"
      ├─ used  search/d69a6fef-c966-4370-8077-33a0d03c54ce  Searched PubMed for "Periglandula Convolvulaceae ergot alkaloids symbiosis fungal"
      ├─ used  search/e3cc2f53-a48a-4894-912e-0049ff2d61d5  Searched PubMed for "Argyreia nervosa Hawaiian baby woodrose LSA toxicology adverse"
      ├─ used  search/7cbf40b3-6863-415f-9bac-6902aec900d0  Searched WebSearch for "LSA ergine Schedule III DEA Controlled Substances Act legal status United States"
      ├─ used  search/3684ff6c-51cc-4a68-aacf-3ded653e4986  Searched WebSearch for "Ipomoea tricolor violacea taxonomy accepted species POWO synonym morning glory"
      ├─ used  search/73c9c100-c350-4d9e-8d9e-38fafb6c9403  Searched Erowid for "morning glory legal status"
      ├─ used  search/97cc4627-337e-4800-a4c7-dab9d895409f  Searched Crossref via verify_doi for "DOI verification for Meira et al. 2012 and Mercurio et al. 2017"
      ├─ used  search/4edb6a83-d786-4d55-922a-8adc01b69204  Searched WebSearch for "Albert Hofmann ololiuqui morning glory 1960 discovery history"
      ├─ used  search/45c7e2b5-fcd1-45c4-957f-a174d63683c8  Searched WebSearch for "Ipomoea tricolor pesticide treated commercial ornamental seeds"
      ├─ used  search/819bb75d-a5cc-4210-9f03-f35f3c6578fe  Searched ClinicalTrials.gov for "morning glory LSA ergine lysergic acid amide"
      ├─ used  search/009a19fb-b322-4039-87f1-796bfb317149  Searched DrugWise.org.uk for "morning glory seeds UK harm reduction"
      ├─ used  search/37f1a9ee-001c-496a-8560-f473c1890b47  Searched PubChem for "Ergine CID 442072, Isoergine CID 12309749, Ergonovine CID 443884"
      ├─ used  search/818d0964-f89f-4e36-8c93-7f3f65e5a2b6  Searched Multiple sources for "I. tricolor vs I. violacea taxonomy"
      ├─ used  search/b156535d-f0ae-44a7-8cb6-e47ed38e3ddf  Searched OpenAlex for "ergine LSA binding affinity 5-HT2A receptor dopamine hallucinogen mechanism"
      └─ used  search/eebf103a-5f52-47ea-b07e-2c9caa34ec8e  Searched PubMed for "ergot alkaloid vasoconstriction serotonin triptan interactions"
├─ informed_by  section/alkaloid-profile.full@2
  ├─ used  version/2  Revision 2
  ├─ used  claim/943e3bf3-b66a-494e-8db6-46151959e7f0  Claim in alkaloid-profile — inconclusive  working
    ├─ derived_from  issue/notice@64878b43a1d2  Issued notice
    ├─ derived_from  issue/info_card@bb0fdfde157d  Issued info_card
    ├─ derived_from  issue/emergency@3f0909c25c71  Issued emergency
    ├─ derived_from  issue/notice@f069a9dea47b  Issued notice
    ├─ derived_from  issue/info_card@6f2c631afd01  Issued info_card
    ├─ derived_from  issue/emergency@c15c760aabf6  Issued emergency
      ├─ used  claim/384e84d3-c365-4ed1-a399-c904dd4a0c59  Claim in summary — supported
      ├─ used  claim/76f6820b-d08f-4cbb-8c24-ee97dbe783d3  Claim in summary — supported
      ├─ used  claim/d905b629-a34f-4899-a942-dfb0b9bb8e76  Claim in safety — partially_supported
      ├─ used  claim/fbe6f3ec-aa30-421b-b71b-9371b7bd635a  Claim in neuroscience — supported
      ├─ used  claim/12c83a40-97e6-486e-b6c6-36d3c0fe5ccd  Claim in summary — inconclusive  working
      ├─ used  claim/47473ed9-9633-442f-966a-5f7d3a9e9b1b  Claim in safety — supported
      ├─ used  claim/1739418c-32e9-465a-bc52-af1a0c81c19d  Claim in history — supported
      ├─ used  claim/637ee93f-94c4-42fc-a3a9-510ce4c6a31e  Claim in preparations — supported
      ├─ used  claim/9465b379-8c19-4bb0-afa1-d6a1dc9ba981  Claim in preparations — supported
      ├─ used  claim/90a8b436-c871-4a46-b0bd-6cb5705e8d3c  Claim in summary — supported
      ├─ used  claim/b7f902c6-f6ad-4cbc-91b7-3d41001980e4  Claim in safety — supported
      ├─ used  claim/7aafe027-03db-4c84-8b7f-74a7f6ce9c93  Claim in botanical-overview — not_supported  working
      ├─ used  claim/0a07fa21-3ded-46bd-b3d3-7e9f4b54a522  Claim in preparations — supported
      ├─ used  claim/c6ebff79-25c1-4380-a4e0-bca3cd057d29  Claim in summary — partially_supported
      ├─ used  claim/29a66bbb-c442-4357-aba7-2c2c13b418a3  Claim in safety — supported
      ├─ used  claim/ac72ec8e-de7e-4d97-b445-bc907e3ccbad  Claim in safety — partially_supported
      ├─ used  claim/69c3b73b-d03d-4aed-aba6-4aa749daf0ce  Claim in summary — inconclusive  working
      ├─ used  claim/a87758d6-3520-479f-8f0f-b9099a70cbc3  Claim in neuroscience — supported
      ├─ used  claim/1f69c620-df32-42af-a8e8-ebfd04264ad1  Claim in safety — supported
      ├─ used  claim/f6b8362c-91b7-48df-a5fc-1b112a87669f  Claim in safety — inconclusive  working
      ├─ used  claim/dcf0730b-9d9d-483c-ad85-1edafe017b1a  Claim in safety — supported
      ├─ used  claim/daa8dd5a-79db-4cd2-87c4-8c022efea7c9  Claim in neuroscience — supported
      ├─ used  claim/94147a59-89ff-4f01-b8d2-87be71f0bf5f  Claim in summary — supported
      ├─ used  claim/baca0dd5-ef67-48e2-986a-43e34a45efbe  Claim in safety — supported
      ├─ used  claim/d2590d39-f499-4f4a-9344-cc6af0b099c5  Claim in neuroscience — supported
      ├─ used  claim/86c87eb7-2994-4d21-8060-f4fd2e9c1e19  Claim in history — supported
      ├─ used  claim/904063da-2476-4a14-b03e-eb82d2b92110  Claim in botanical-overview — partially_supported
      ├─ used  claim/c6a587ba-8e4b-494e-9a01-1b4a7ea6d343  Claim in botanical-overview — inconclusive  working
      ├─ used  claim/348e5f92-53e3-43f9-9d83-a84ad9676ab1  Claim in safety — inconclusive  working
      ├─ used  claim/8aadf1f6-ceb7-4caf-9d23-98c4a7a26395  Claim in history — inconclusive  working
      ├─ used  claim/551b2d5c-b871-4faa-9064-861983c3af15  Claim in history — inconclusive  working
      ├─ used  claim/a749f0ff-6c18-4f5d-90fe-2ff09682e996  Claim in botanical-overview — inconclusive  working
      ├─ used  claim/5e2745a4-e635-4cc5-a12c-aac8210e4507  Claim in botanical-overview — partially_supported
      ├─ used  claim/acd7a2b3-b383-433a-b371-b656bb8246af  Claim in botanical-overview — not_supported  working
      ├─ used  claim/f699d2f7-ea71-4650-ab2c-fa98abf10d94  Claim in preparations — supported
      ├─ used  claim/bfedeab9-b6cf-4d99-8be8-b3a99f87acf9  Claim in preparations — supported
      ├─ used  claim/6c520a0f-f92b-47db-af7b-cbe2dd286292  Claim in preparations — inconclusive  working
      ├─ used  claim/e05afcde-997e-425e-9b08-1567911e2657  Claim in neuroscience — inconclusive  working
      ├─ used  claim/6b1219df-5342-4e8a-8c13-448d2f7725b7  Claim in neuroscience — inconclusive  working
      ├─ used  claim/fa605641-db26-43c9-b783-86c908e385ca  Claim in safety — supported
      ├─ used  claim/08e06c34-78cc-4d1d-af90-3ab7029b468c  Claim in safety — supported
      ├─ used  claim/a82d1fa8-b290-4915-9940-df8124c50985  Claim in safety — supported
      ├─ used  claim/84a70fae-ace1-45aa-ad80-005ff950b30e  Claim in preparations — supported
      ├─ used  claim/1b4d9c96-963c-4e18-84de-c7ec0ee55565  Claim in neuroscience — supported
      ├─ used  claim/b0ae9cce-1d9c-4167-a3a7-93a7b0429899  Claim in neuroscience — supported
      ├─ used  claim/d92cc94f-18ed-4666-86d8-8533176fbd05  Claim in safety — supported
      ├─ used  claim/e69fd43f-1790-44f1-b7b0-798ed05fadad  Claim in safety — supported
      └─ used  claim/48191237-66f1-4b57-8f54-12624deb9efb  Claim in safety — inconclusive  working
… closure truncated at 200 nodes

indented by distance from this node, not by parentage

1Provenance card

the boundary, as counts

Sources

2018 with DOI

0 strong · 16 moderate · 4 weak

Compilations

12026-05-14T08:16:28.841Z

pipeline-v5 · prompt hash not recorded — run predates 2026-09

Decisions

22last ruled 2026-06-04

0 awaiting a ruling

Issued documents

62026-10-19T20:33:08.264Z

notice · info card · emergency

Searches

171 with no results

queries and counts on the build

Claims checked

5639 supported

39 supported · 17 not

Correspondence

0received

consent field ships in Phase 4

Edges

186

derivations recorded for this entity

Complete over 20 sources, 1 compilation, and 22 decisions.Not here: the private journal (never).Working material — drafts, discards, unsupported claims — is listed below and readable on the working page.Cite: psychedex.org/substances/morning-glory/archive

2Build

one panel per compilation run

generation run 2026-05-14

57 min completedmodel pipeline-v5plan not recordedrun/4f82a52f…

Selection

results seen88
selected by the model37
consumed as sources20

Verification

claims checked56
supported34
partially supported5
not supported2
inconclusive15
  • record
  • seen / partial
  • working

The model's own caveats

  • safety_data_unverified
  • sparse_evidence
  • contradictory_sources
  • structural_inference
  • contaminant_data_absent

Reproduce

inputs
20 source keys (listed under Sources)
plan
not recorded — template version, prompt hash and git SHA are written from 2026-09 onward
model
pipeline-v5
streams
none — agent transcripts are persisted from 2026-09 onward
17 searches — query, source, results, what was kept and why
17 searches for this run
#sourcequeryseenkeptrationale
1WebSearchIpomoea tricolor violacea taxonomy accepted species POWO synonym morning glory101Critical taxonomic clarification affecting the substance identity
2OpenAlexmorning glory Ipomoea ergine lysergic acid amide psychoactive105Directly relevant to morning glory alkaloid chemistry, quantification, and pharmacology
3WebSearchLSA ergine Schedule III DEA Controlled Substances Act legal status United States101Legal status verification
4PubChemergine / lysergic acid amide13Chemical identity verification of primary alkaloids
5PubMedIpomoea violacea ergot alkaloids64Core papers on alkaloid characterization and recreational use
6PubMedPeriglandula Convolvulaceae ergot alkaloids symbiosis fungal95Established that ergot alkaloids in morning glories come from heritable Periglandula fungal endosymbionts
7PubMedArgyreia nervosa Hawaiian baby woodrose LSA toxicology adverse22Critical safety data for LSA from closely related Convolvulaceae - A. nervosa contains same alkaloid
8WebSearchIpomoea tricolor pesticide treated commercial ornamental seeds101Key harm reduction concern for commercial seed ingestion
9WebSearchAlbert Hofmann ololiuqui morning glory 1960 discovery history101Historical context for morning glory research
10Erowidmorning glory legal status11Authoritative harm reduction database on legal status
11ClinicalTrials.gov · absencemorning glory LSA ergine lysergic acid amide00Confirmed absence of clinical trial data
12Crossref via verify_doiDOI verification for Meira et al. 2012 and Mercurio et al. 201722DOI verification for key alkaloid quantification papers
13DrugWise.org.ukmorning glory seeds UK harm reduction12UK harm reduction context and pesticide safety concern
14PubChemErgine CID 442072, Isoergine CID 12309749, Ergonovine CID 44388433Chemical identity verification of primary psychoactive alkaloids
15Multiple sourcesI. tricolor vs I. violacea taxonomy42Critical taxonomic disambiguation for accurate article writing
16OpenAlexergine LSA binding affinity 5-HT2A receptor dopamine hallucinogen mechanism62Best available pharmacology data for ergine mechanism, by analogy
17PubMedergot alkaloid vasoconstriction serotonin triptan interactions32Drug interaction and dependence data for ergot alkaloid class
56 claims by section — every cited sentence, checked against its source
safety16 · 13 ok
  • The triptan–ergot interaction is of particular concern given the vasoconstrictive properties of both drug classessupported

    Of concern: additive vasoconstriction with ergots is likely. s40263-012-0002-5

  • Claim in safety — inconclusiveinconclusiveworking →

  • Serotonergic agents (SSRIs, SNRIs, MAOIs, triptans): Additive serotonergic activity at 5-HT₂A and 5-HT₁A receptors raises theoretical serotonin syndrome risksupported

    DDIs can occur at PK and PD levels leading to serotonin toxicity. s12248-008-9028-5

  • In a prospective study of A. nervosa seeds at body-weight-normalized doses, 3 of 4 subjects experienced severe adverse effects: cardiovascular dysregulation in 2 subjects and a psychosis-like state in 1; all recovered completely within 9 hourssupported

    Study halted due to severe adverse effects: cardiovascular dysregulation in 2/4 subjects, psychosis-like state in 1. All recovered within 9h. Interindividual variability despite normalized doses. j.forsciint.2011.06.025

  • A fatal case involved an individual who fell from a building during LSA intoxication with co-ingested THC and ethanol (blood LSA concentration 4.9 µg/L).supported

    One fatality (fall from building). LSA in blood 4.9 and 1.8 ug/L. Co-use THC and ethanol in fatal case. j.forsciint.2009.11.017

  • Batch alkaloid variability is a separate risk vector: 2 of 5 commercial lots tested contained zero detectable ergot alkaloids, making dose prediction from seed count unreliablesupported

    3 of 5 seed lots contained ergot alkaloids. Single-seed variability noted. s00216-016-9322-5

  • Acute psychological adverse effects include anxiety, panic, confusion, and psychosis-like states at higher doses or in susceptible individuals. Suicidal ideation has been documented in 2 recreational users who ingested A. nervosa and Ipomoea seedspartially supported

    psychosis-like state in 1. Interindividual variability despite normalized doses. j.forsciint.2011.06.025

  • Acute psychological adverse effects include anxiety, panic, confusion, and psychosis-like states at higher doses or in susceptible individuals. Suicidal ideation has been documented in 2 recreational users who ingested A. nervosa and Ipomoea seedssupported

    Suicidal ideation in 2 subjects. Common co-use with cannabis. Doses and symptoms comparable to medical case reports. pmid:23662334

  • Claim in safety — inconclusiveinconclusiveworking →

  • By analogy with LSD and other serotonergic psychedelics, rapid tachyphylaxis — tolerance developing within 3–4 days of repeated use — is expected, with cross-tolerance to LSD, psilocybin, and other 5-HT₂A agonists.partially supported

    Cross-tolerance between LSD and other serotonergic hallucinogens established. j.neuropharm.2011.01.017

  • Ergoline compounds as a class show low physical dependence liability, consistent with their low compulsive use patterns in recreational settingssupported

    Updated overview of psychedelics including ergolines. Limited dependence liability for psychedelics. 17512433.2023.2279192

  • Ergotamine (a related ergot alkaloid used medicinally) can produce a physical dependence syndrome characterized by a self-sustaining headache-medication cycle; whether ergine produces analogous dependence at recreational doses is unknown.supported

    Physical dependency on ergotamine exists: irresistible use, headache/medication cycle as withdrawal. Variable susceptibility and tolerance. pmid:3087616

  • The sole documented fatality involving LSA-containing seeds involved co-ingestion of ethanol and THC.supported

    One fatality (fall from building). Co-use THC and ethanol in fatal case. j.forsciint.2009.11.017

  • CYP2D6 inhibitors (fluoxetine, paroxetine, bupropion): May increase ergine plasma levels and effect duration via reduced hepatic metabolism.supported

    Reviews CYP2D6 role in indolealkylamine metabolism including lysergic acid amides. DDIs can occur at PK and PD levels. s12248-008-9028-5

  • Claim in safety — inconclusiveinconclusiveworking →

  • CYP2D6 poor metabolizers: May experience prolonged and more intense effects at standard doses.supported

    CYP2D6 polymorphism as additional risk factor. s12248-008-9028-5

alkaloid-profile8 · 5 ok
  • Claim in alkaloid-profile — inconclusiveinconclusiveworking →

  • Claim in alkaloid-profile — inconclusiveinconclusiveworking →

  • They are produced by a heritable fungal endosymbiont, Periglandula clandestina sp. nov. (Clavicipitaceae), recently described from I. tricolor seed coatssupported

    Periglandula clandestina sp. nov., the ergot alkaloid-producing fungal symbiont of I. tricolor. Isolated from seed coats; genome sequenced. 00275514.2025.2483634

  • The fungi are vertically transmitted through seeds and produce alkaloids that are translocated via peltate glandular trichomes into host plant tissuessupported

    Trichomes secrete sesquiterpenes and palmitic acid and absorb ergot alkaloids from epibiotic Periglandula. Dual function in metabolic dialogue. toxins7041355

  • Alkaloids are distributed throughout the entire plant — roots, stems, leaves, flowers, and seeds — not solely in seeds.supported

    Ergot alkaloids in roots of E+ plants. Defensive symbiosis supported. s10886-019-01109-w

  • Minor clavine alkaloids include chanoclavine, elymoclavine, lysergol, and chanoclavine acid — the last of these first isolated from Ipomoea materialsupported

    Chanoclavine acid first isolated from Ipomoea violacea. s00253-024-13157-8

  • Claim in alkaloid-profile — inconclusiveinconclusiveworking →

  • General principles from the Periglandula literature suggest alkaloid content is highest in seeds and youngest leavessupported

    Periglandula ipomoeae found in young folded leaves, mature leaves, flower buds, mature flowers, young and mature seeds of I. asarifolia. Density correlates with glandular trichome density. jof8080823

neuroscience8 · 6 ok
  • Blood concentrations: 4.9 µg/L (fatal case, co-ingested THC and ethanol) and 1.8 µg/L (surviving witness)supported

    LSA in blood 4.9 and 1.8 ug/L. Co-use THC and ethanol in fatal case. j.forsciint.2009.11.017

  • Its primary psychoactive mechanism is presumed to be 5-HT₂A receptor partial agonism, the same mechanism established for LSD, psilocin, and other classical serotonergic hallucinogenssupported

    5-HT2A primary mediator of hallucinogen effects. Indoleamines (including LSD) are non-selective for serotonin receptors compared to phenylalkylamines. j.neuropharm.2011.01.017

  • Its primary psychoactive mechanism is presumed to be 5-HT₂A receptor partial agonism, the same mechanism established for LSD, psilocin, and other classical serotonergic hallucinogenssupported

    Ergolines: increased serotonin 5-HT receptor activation. 17512433.2023.2279192

  • Claim in neuroscience — inconclusiveinconclusiveworking →

  • Claim in neuroscience — inconclusiveinconclusiveworking →

  • Urinary metabolites: 2-hydroxy-3-oxo-LSA and 2-hydroxy-3-oxo-ergonovine identifiedsupported

    2-hydroxy-3-oxo metabolites of LSA and ergonovine identified. j.forsciint.2009.11.017

  • CYP2D6 is identified as the principal enzyme in indolealkylamine metabolism, including lysergic acid amidessupported

    Reviews CYP2D6 role in indolealkylamine metabolism including lysergic acid amides. s12248-008-9028-5

  • Poor metabolizers may experience prolonged and more intense effects at any given dose.supported

    CYP2D6 polymorphism as additional risk factor. s12248-008-9028-5

preparations7 · 6 ok
  • Dose estimates derive from forensic calculations and user-report analyses rather than controlled dose-finding studies:supported

    Analysis of web-reported recreational use. Doses and symptoms comparable to medical case reports. pmid:23662334

  • Dose estimates derive from forensic calculations and user-report analyses rather than controlled dose-finding studies:supported

    GC/MS analysis of I. violacea seeds (police seizures) and commercial seeds. Police seizure sample: 0.062% LSA. s41935-017-0016-8

  • They are derived from forensic alkaloid calculations and user-report analysissupported

    GC/MS analysis of I. violacea seeds (police seizures). Police seizure sample: 0.062% LSA (300 mg seeds, ~8 seeds). s41935-017-0016-8

  • They are derived from forensic alkaloid calculations and user-report analysissupported

    Analysis of web-reported recreational use. Doses and symptoms comparable to medical case reports. pmid:23662334

  • Claim in preparations — inconclusiveinconclusiveworking →

  • Batch variability: Alkaloid content varies substantially between commercial batches; some lots contain no detectable ergot alkaloidssupported

    3 of 5 seed lots contained ergot alkaloids. Single-seed variability noted. s00216-016-9322-5

  • CYP2D6 polymorphism: Poor metabolizers likely experience more prolonged and intense effects at any given dosesupported

    CYP2D6 polymorphism as additional risk factor. s12248-008-9028-5

summary7 · 5 ok
  • Morning glory refers primarily to Ipomoea tricolor Cav. (Convolvulaceae), a fast-growing annual vine whose seeds contain ergoline alkaloids — principally lsa (ergine, d-lysergic acid amide) — produced not by the plant itself but by a heritable fungal endosymbiont, Periglandula clandestinasupported

    Periglandula clandestina sp. nov., the ergot alkaloid-producing fungal symbiont of I. tricolor. Isolated from seed coats; genome sequenced. 00275514.2025.2483634

  • Ergine is a semirigid ergoline structurally related to LSD; its primary psychoactive mechanism is presumed to be 5-HT₂A receptor partial agonism, inferred from structural analogy rather than published binding affinity datasupported

    5-HT2A primary mediator of hallucinogen effects. Indoleamines (including LSD) are non-selective for serotonin receptors compared to phenylalkylamines. j.neuropharm.2011.01.017

  • Claim in summary — inconclusiveinconclusiveworking →

  • Alkaloid content varies substantially between seed batches, cultivars, and commercial sources; a significant fraction of commercially available seeds contain no detectable ergot alkaloids.supported

    3 of 5 seed lots contained ergot alkaloids. Single-seed variability noted. s00216-016-9322-5

  • Documented adverse events include cardiovascular dysregulation, psychosis-like states, and suicidal ideation in case reports involving LSA-containing seedspartially supported

    cardiovascular dysregulation in 2/4 subjects, psychosis-like state in 1. All recovered within 9h. j.forsciint.2011.06.025

  • Claim in summary — inconclusiveinconclusiveworking →

  • Dependence liability is unstudied but presumed low based on ergoline class datasupported

    Updated overview of psychedelics including ergolines. Limited dependence liability for psychedelics. 17512433.2023.2279192

botanical-overview6 · 2 ok
  • The genus Ipomoea comprises 600–700 species, making it the largest genus within Convolvulaceaepartially supported

    600-700 species of Ipomoea in Convolvulaceae, found throughout tropical/subtropical regions. s0102-695x2012005000025

  • Approximately 40% of species in the tribe Ipomoeeae harbor heritable fungal endosymbionts of the genus Periglandula that produce ergot alkaloids; however, multiple commercially sold ornamental species lack these symbionts entirely.partially supported

    ~40% of Ipomoeeae species have heritable endosymbiotic fungi producing ergot alkaloids, indole diterpenes, or swainsonine. nph.18785

  • Claim in botanical-overview — inconclusiveinconclusiveworking →

  • Claim in botanical-overview — not_supportednot supportedworking →

  • Claim in botanical-overview — not_supportednot supportedworking →

  • Claim in botanical-overview — inconclusiveinconclusiveworking →

history4 · 2 ok
  • The genus Ipomoea comprises 600–700 species within the family Convolvulaceae, distributed primarily across tropical and subtropical regionssupported

    600-700 species of Ipomoea in Convolvulaceae, found throughout tropical/subtropical regions. s0102-695x2012005000025

  • Claim in history — inconclusiveinconclusiveworking →

  • A reemergence occurred in Poland and elsewhere in the 2010s, with systematic analysis of web-reported use cases confirming symptoms comparable to earlier medical case reportssupported

    Analysis of web-reported recreational use. Reoccurrence since 1968. Doses and symptoms comparable to medical case reports. pmid:23662334

  • Claim in history — inconclusiveinconclusiveworking →

3Sources

20 consumed · sorted by year · feeds = sections resting on it

Sources
yearsourcetierstatusfeeds
2025A new species of Periglandula symbiotic with the morning glory Ipomoea tricolorHazel CM, Panaccione DG · Mycologiadoi:10.1080/00275514.2025.2483634moderateconsumed2 sections
2024An unexpected role of EasD: catalyzing the conversion of chanoclavine aldehyde to chanoclavine acidYu ZP, An C, Yao Y, Yan JZ, Gao SS, Gu YC, Wang CY, Cui C · Applied Microbiology and Biotechnologydoi:10.1007/s00253-024-13157-8moderateconsumed1 section
2023Phylogenetic patterns of bioactive secondary metabolites produced by fungal endosymbionts in morning glories (Ipomoeeae, Convolvulaceae)Quach QN, Clay K, Lee ST, Gardner DR, Cook D · The New Phytologistdoi:10.1111/nph.18785moderateconsumed1 section
2023Stimulant and hallucinogenic novel psychoactive substances; an updateSchifano F, Vento A, Scherbaum N, Guirguis A · Expert Review of Clinical Pharmacologydoi:10.1080/17512433.2023.2279192moderateconsumed3 sections
2022How and Where Periglandula Fungus Interacts with Different Parts of Ipomoea asarifoliaOlaranont Y, Stewart AB, Songnuan W, Traiperm P · Journal of Fungidoi:10.3390/jof8080823moderateconsumed1 section
2021Distribution of Ipomoea violacea (Convolvulaceae): patterns, gaps and reports for its occurrence in Brazil and West Tropical AfricaAlencar J, Staples GW, Budden A · Rodriguesiadoi:10.1590/2175-7860202172034moderateconsumedcited only
2019Decreased Root-Knot Nematode Gall Formation in Roots of the Morning Glory Ipomoea tricolor Symbiotic with Ergot Alkaloid-Producing Fungal Periglandula Sp.Durden L, Wang D, Panaccione D, Clay K · Journal of Chemical Ecologydoi:10.1007/s10886-019-01109-wmoderateconsumed1 section
2018Ergot Alkaloids and their Hallucinogenic Potential in Morning GloriesSteiner U, Leistner E · Planta Medicadoi:10.1055/a-0577-8049moderateconsumed4 sections
2017GC/MS analysis of morning glory seeds freely in commerce: can they be considered herbal highs?Mercurio I, Melai P, Capano D, Ceraso G, Carlini L, Bacci M · Egyptian Journal of Forensic Sciencesdoi:10.1186/s41935-017-0016-8moderateconsumed2 sections
2017Herbal Highs: Review on Psychoactive Effects and NeuropharmacologyGraziano S, Orsolini L, Rotolo MC, Tittarelli R, Schifano F, Pichini S · Current Neuropharmacologydoi:10.2174/1570159x14666161031144427moderateconsumedcited only
2016Identification and determination of ergot alkaloids in Morning Glory cultivarsNowak J, Wozniakiewicz M, Klepacki P, Sowa A, Koscielniak P · Analytical and Bioanalytical Chemistrydoi:10.1007/s00216-016-9322-5moderateconsumed4 sections
2015The key role of peltate glandular trichomes in symbiota comprising clavicipitaceous fungi of the genus Periglandula and their host plantsSteiner U, Kucht SH, Ahimsa-Muller MA, Grundmann N, Li SM, Drewke C, Leistner E · Toxinsdoi:10.3390/toxins7041355moderateconsumed1 section
2013Recreational use of D-lysergamide from the seeds of Argyreia nervosa, Ipomoea tricolor, Ipomoea violacea, and Ipomoea purpurea in PolandJuszczak GR, Swiergiel AH · Journal of Psychoactive Drugspmid:23662334moderateconsumed4 sections
2012Drug interactions with triptans: which are clinically significant?Rolan PE · CNS Drugsdoi:10.1007/s40263-012-0002-5moderateconsumed1 section
2012Ipomoea genus review — traditional uses, chemistry, and biological activitiesMeira M, Pereira da Silva E, David JM, David JP · Revista Brasileira de Farmacognosiadoi:10.1590/s0102-695x2012005000025weakconsumed2 sections
2012Variable adverse effects in subjects after ingestion of equal doses of Argyreia nervosa seedsKremer C, Paulke A, Wunder C, Toennes SW · Forensic Science Internationaldoi:10.1016/j.forsciint.2011.06.025weakconsumed2 sections
2011Multiple receptors contribute to the behavioral effects of indoleamine hallucinogensHalberstadt AL, Geyer MA · Neuropharmacologydoi:10.1016/j.neuropharm.2011.01.017moderateconsumed3 sections
2010Two cases of lysergamide intoxication by ingestion of seeds from Hawaiian Baby WoodroseKlinke HB, Muller IB, Steffenrud S, Dahl-Sorensen R · Forensic Science Internationaldoi:10.1016/j.forsciint.2009.11.017weakconsumed3 sections
2008Indolealkylamines: biotransformations and potential drug-drug interactionsYu AM · The AAPS Journaldoi:10.1208/s12248-008-9028-5moderateconsumed3 sections
1986Ergotamine tartrate dependency: features and possible mechanismsSaper JR, Jones JM · Clinical Neuropharmacologypmid:3087616weakconsumed1 section
—Searched ClinicalTrials.gov for "morning glory LSA ergine lysergic acid amide" — no resultsabsenceno results—

4Docket

one filing per activity — decisions, correspondence, reports

  1. 0012026-03-17importImported from Curiosity v1

    imported 2026-03; original sourcing not recoverable

    psx:substance/morning-glory/import/curiosity-v1
  2. 0022026-03-17publicationPublication — backfill
  3. 0032026-03-17revisionRevision 1
  4. 0042026-05-14revisionRevision 2

    Initial LLM generation (plant pipeline v1, wiki, prose phase)

    psx:substance/morning-glory/version/2
  5. 0052026-06-04proposal17 value proposals approved together

    one review action inferred from a shared reviewer and instant — the graph records one activity per proposal

    17 items in this filing

    • contraindication · pregnancy_breastfeeding
    • contraindication · psychiatric
    • contraindication · other
    • contraindication · psychiatric
    • contraindication · metabolic
    • contraindication · hepatic
    • contraindication · other
    • dose_tier · threshold
    • dose_tier · light
    • dose_tier · common
    • dose_tier · strong
    • dose_tier · heavy
    • toxicity
    • dependence · full
    • withdrawal
    • tolerance
    psx:substance/morning-glory/proposal/contraindication/6a6c2927-abef-40a8-966c-c183ec8d8699
  6. 0062026-06-04publicationPublication — backfill

5Issued documents

what the notice, info card and emergency page said, by hash

Issued documents
documentcontent hashissuedfrom versionsuperseded
emergencyc15c760aabf6f0fcf5b6fc6b…2026-10-19 20:33Revision 2current
info_card6f2c631afd01cfd5f9bf2978…2026-10-19 20:33Revision 2current
noticef069a9dea47b308467344618…2026-10-19 20:33Revision 2current
emergency3f0909c25c714d225b4bb3e3…2026-09-04 04:31Revision 2superseded2026-10-19
info_cardbb0fdfde157d1d1434180791…2026-09-04 04:31Revision 2superseded2026-10-19
notice64878b43a1d2932a5305f55b…2026-09-04 04:31Revision 2superseded2026-10-19